Resveratrol is the most famous longevity molecule in the world, and it has a problem that its fame has largely papered over.
Almost none of it reaches your bloodstream intact.
Oral resveratrol is absorbed reasonably well but then hit hard by first-pass metabolism — rapidly glucuronidated and sulfated in the intestinal wall and liver. Studies measuring plasma levels after oral dosing find unmetabolised resveratrol at trace concentrations, with the overwhelming majority circulating as conjugated metabolites whose activity is still debated.
Pterostilbene is the same molecular scaffold with two methoxy groups where resveratrol has hydroxyls. That change materially altered pharmacokinetics in animal studies, but equivalent comparative bioavailability data in humans are limited.
Why Two Methyl Groups Change the Outcome
Those hydroxyl groups on resveratrol are precisely the sites where phase II conjugation enzymes attach. Replace them with methoxy groups and you remove the attachment points. The molecule becomes more lipophilic and considerably more resistant to rapid conjugation.
Kapetanovic and colleagues (2011) ran a direct pharmacokinetic comparison in rats. Pterostilbene showed roughly 80% oral bioavailability against approximately 20% for resveratrol, with a substantially longer half-life. Preclinical
Increased lipophilicity also means better membrane crossing generally — including the blood-brain barrier, which is why pterostilbene shows up more often in cognitive research while resveratrol dominates metabolic and cardiovascular work.
Side by Side
| Trans-Resveratrol | Pterostilbene | |
|---|---|---|
| Natural source | Japanese knotweed, red wine, grape skin | Blueberries, Pterocarpus heartwood |
| Structure | Three hydroxyl groups | Two methoxy + one hydroxyl |
| Oral bioavailability in a rat comparison | ~20% | ~80% |
| Half-life | Short | Considerably longer |
| CNS evidence | Human and preclinical studies | Mostly preclinical studies |
| SIRT1 activation | Well documented | Documented |
| Human trial volume | Extensive | Limited |
| Strongest area | Metabolic, cardiovascular | Cognitive, lipid, antioxidant |
| Typical daily dose | 250–1000 mg | 50–250 mg |
What Human Trials Show for Each
Resveratrol
Timmers and colleagues (2011), in Cell Metabolism, gave 150 mg daily of resveratrol to obese men for 30 days. They observed reduced sleeping metabolic rate, decreased intrahepatic lipid content, improved muscle mitochondrial function and lowered inflammatory markers — a pattern the authors described as resembling caloric restriction. Human trial, small
Tomé-Carneiro and colleagues (2012) reported improved inflammatory profiles in cardiovascular disease patients on a bioavailable grape-resveratrol formulation. Human trial
It's a genuine body of human evidence — though results across the wider literature are mixed, and some well-designed trials have found no effect. That inconsistency is plausibly explained in part by the bioavailability problem above.
Pterostilbene
Riche and colleagues (2013) ran a randomised, double-blind, placebo-controlled trial of pterostilbene in adults with hypercholesterolaemia and reported effects on lipid parameters and blood pressure. Human trial That remains one of the few controlled human pterostilbene trials published — the compound's stronger evidence remains preclinical, particularly the cognitive and neuroprotective rodent work.
So there's a genuine trade-off: resveratrol has the weaker molecule with the stronger human dataset. Pterostilbene has the better molecule with less human data. That's the honest state of the field, and anyone presenting it as settled is overreaching.
Which Fits Which Goal
Trans-resveratrol — if metabolic and cardiovascular support is the priority, and you want the compound with the largest volume of human trials. Form matters enormously: the trans isomer is the active one, and cis conversion under UV exposure inactivates it. Trans-Resveratrol in a light-protected, verified-isomer form is not the same product as generic resveratrol.
Pterostilbene has stronger comparative pharmacokinetics in rats and far less human outcome evidence. Pterostilbene should not be assumed to deliver greater cognitive benefit simply because animal bioavailability is higher.
Both — no controlled trial has shown that combining them produces better outcomes than either compound alone. A larger stack adds cost and interaction uncertainty, not proven synergy.
One safety note worth taking seriously
Resveratrol inhibits several cytochrome P450 enzymes and has antiplatelet activity. If you take anticoagulants, antiplatelet drugs, or medication metabolised through CYP3A4, talk to your doctor before starting either compound. This isn't boilerplate — the interaction is real and documented.
Compare both compounds →References
Kapetanovic IM, et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011;68(3):593–601. Preclinical
Timmers S, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–622. Human trial
Riche DM, et al. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol. 2013;2013:463595. Human trial
These statements have not been evaluated by the Food and Drug Administration. Not intended to diagnose, treat, cure or prevent any disease. Resveratrol and pterostilbene may interact with anticoagulant and antiplatelet medication — consult a qualified healthcare professional before use.
